Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

Clinical Infectious Diseases

Volumn 34, Issue 5, 2002, Pages 563-571

  Denning, David W ^a   Ribaud, Patricia ^b   Milpied, Noel ^c   Caillot, Denis ^d   Herbrecht, Raoul ^e   Haas, Andrea ^f   Thiel, Eckhard ^g   Ruhnke, Markus ^g   Lode, Hartmut ^h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d HÔPITAL DU BOCAGE   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; BRAIN INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FUNGUS CULTURE; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIOGRAPHY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 0036498964     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324620     Document Type: Article

References (41)

1. Invasive aspergillosis
2. Chronic necrotisong pulmonary aspergillosis: Approach to management
3. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
4. Therapeutic outcome of invasive aspergillosis
5. A double-blind randomised controlled trial of Amphocil (ABCD) versus amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients
6. Amphotericin B: 30 Years of clinical experience
7. Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients
8. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis
9. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients
10. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
11. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
12. In vitro activities of amphotericin B, itraconazole, and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates
13. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
14. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis
15. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
16. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
17. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis
18. An EORTC multicentre prospective survey of invasive aspergillosis in cancer patients: Diagnosis and therapeutic outcome
19. NIAID mycoses study group multicenter trial of oral itraconazole therapy of invasive aspergillosis
20. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
21. An EORTC international multicenter randomised trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
22. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases
23. Outcome and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation
24. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by NIAID mycoses study group criteria
25. Localization of aspergillosis to the central nervous system among patients with acute leukemia: Report of 14 cases
26. Aspergillosis among people infected with human immunodeficiency virus: Incidence and survival
27. Treatment of cerebral aspergillosis with itraconazole. Do high doses improve the prognosis?
28. Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature
29. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
30. Fungal pulmonary infections after bone marrow transplantation: Evaluation with radiography and CT
31. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis
32. Invasive pulmonary aspergillosis: MRI, CT, and plain radiographic findings and their contribution for early diagnosis
33. Pulmonary nodules and the CT halo sign
34. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: Use of high resolution computed tomography
35. Treatment of invasive aspergillosis: Relation of early diagnosis and treatment to response
36. Pulmonary fungal infections in patients with hematological malignancies - Diagnostic approaches
37. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
38. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
39. The interaction of azoles with rifampin, phenytoin and carbamazepine: In vitro and clinical observations
40. Drug interaction between cyclosporin and itraconazole in heart and heart-lung and lung transplant recipients with fungal disease